Dr. Darmani's main training has been in the field of pharmacology and will be teaching the core pharmacology course involving introduction to pharmacology, pharmacodynamics and pharmacokinetics.

Dr. Darmani has several avenues of research interest that include:

• developmental effects of drugs of abuse on the newborn
• serotonergic mechanisms of cocaine's actions
• mode of action of antidepressant drugs
• adaptive mechanisms of serotonergic 5-HT2 receptor functions
• the role of delta-9 -THC and synthetic cannabinoids on chemotherapy- and radiotherapy-induced vomiting. His laboratory had the first opportunity to demonstrate the mechanisms of antiemetic actions of marijuana
• one of his more recent research avenues involves the role of osteopathic manipulative medicine on the blood levels of endogenous cannabinoid-like compounds and other pain markers in patients with back pain. He had been successful in obtaining several million dollars of research grants from numerous funding agencies including the Pharmaceutical industry, the National Institute of Drug Abuse, the National Institute of Cancer, the Department of Defense and the Environmental Protection Agency.

Darmani, N.A.; Crim, J.L.; Janoyan, J.J.; Abad, J. and Ramirez, J. (2009) A re-evaluation of the neurotransmitter basis of Chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew. Brain Res. 1248:40-58.

Wang, Y.; Ray, A.P.; McClanahan, B.A. and Darmani, N.A. (2009) The antiemetic interaction of Delta 9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. Pharmacol Biochem Behav. 91(3):367-73

Ray, A. P., Griggs, L. and Darmani, N.A. (2009) Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. Behav. Brain Res. 196(1):30-6

Darmani, N.A.; Wang, Y.; Abad, J.; Ray, A.P.; Thrush, G.R., and Ramirez. J. (2008) Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists. Brain Res. 1214:58-72.